As of 9:30 AM on the 28th, Seegene is trading at 248,100 KRW, down 2.55% from the previous day. The trading volume is 361,842 shares, which is about 15.93% of the previous day's volume. Seegene is known as a developer, manufacturer, and seller of molecular diagnostic reagents.


On August 27, Kim Chung-hyun, a researcher at Mirae Asset Daewoo, stated, "There is little cause for major concern regarding the sharp slowdown in second-half performance. Sales from July to mid-August are at levels similar to May and June. Q4 2020 is the flu season. Entering Phase 3 of COVID-19: the key factors are variant kits and all-in-one kits that combine flu viruses. Compared to global companies, the high dependence on COVID-19 diagnostic kit sales is a disadvantage. If the global spread of COVID-19 enters a declining phase, stock price volatility is likely to increase." He set Seegene's target price at 268,800 KRW.


Over the past five days, individual investors have net sold 400,285 shares of Seegene, while foreigners and institutions have net bought 322,949 shares and 76,872 shares, respectively.



※ Source: AI Investment Assistant AI Rassiro


※ This article was generated in real-time by an automated article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing